Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 469

1.

Are the novel anticoagulants better than warfarin for patients with atrial fibrillation?

Hanley CM, Kowey PR.

J Thorac Dis. 2015 Feb;7(2):165-71. doi: 10.3978/j.issn.2072-1439.2015.01.23. Review.

PMID:
25713732
[PubMed]
Free Article
2.

Efficacy and safety of oral anticoagulants versus aspirin for patients with atrial fibrillation: a meta-analysis.

Zhang JT, Chen KP, Zhang S.

Medicine (Baltimore). 2015 Jan;94(4):e409. doi: 10.1097/MD.0000000000000409.

PMID:
25634169
[PubMed - in process]
3.

[Clinical implications of edoxaban in the current scenario of oral anticoagulants].

De Caterina R.

G Ital Cardiol (Rome). 2014 Dec;15(12):27-9. doi: 10.1714/1744.18990. Italian.

PMID:
25621575
[PubMed - in process]
4.

Intratumoral Hemorrhage in a Patient with Malignant Meningioma under Anticoagulant Therapy.

Ito Y, Nakajima M, Watari M, Sakamoto T, Hashimoto Y, Tajiri S, Takada A, Ando Y.

J Stroke Cerebrovasc Dis. 2015 Jan 22. pii: S1052-3057(14)00566-7. doi: 10.1016/j.jstrokecerebrovasdis.2014.11.008. [Epub ahead of print]

PMID:
25620713
[PubMed - as supplied by publisher]
5.

Have a high index of suspicion for atrial fibrillation.

Leo M, Betts T.

Practitioner. 2014 Oct;258(1775):15-20, 2.

PMID:
25591283
[PubMed - indexed for MEDLINE]
6.

Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: The SAMURAI-NVAF Study.

Toyoda K, Arihiro S, Todo K, Yamagami H, Kimura K, Furui E, Terasaki T, Shiokawa Y, Kamiyama K, Takizawa S, Okuda S, Okada Y, Kameda T, Nagakane Y, Hasegawa Y, Mochizuki H, Ito Y, Nakashima T, Takamatsu K, Nishiyama K, Kario K, Sato S, Koga M; SAMURAI Study Investigators.

Int J Stroke. 2015 Jan 12. doi: 10.1111/ijs.12452. [Epub ahead of print]

PMID:
25581108
[PubMed - as supplied by publisher]
7.

Direct oral anticoagulants: new drugs and new concepts.

Levy JH, Spyropoulos AC, Samama CM, Douketis J.

JACC Cardiovasc Interv. 2014 Dec;7(12):1333-51. doi: 10.1016/j.jcin.2014.06.014.

PMID:
25523529
[PubMed - in process]
8.

Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.

Armbruster HL, Lindsley JP, Moranville MP, Habibi M, Khurram IM, Spragg DD, Berger RD, Calkins H, Marine JE.

Ann Pharmacother. 2015 Mar;49(3):278-84. doi: 10.1177/1060028014563950. Epub 2014 Dec 16.

PMID:
25515868
[PubMed - in process]
9.

Stroke and systemic embolism prevention in patients with atrial fibrillation in belgium: comparative cost effectiveness of new oral anticoagulants and warfarin.

Kongnakorn T, Lanitis T, Annemans L, Thijs V, Goethals M, Marbaix S, Wautrecht JC.

Clin Drug Investig. 2015 Feb;35(2):109-19. doi: 10.1007/s40261-014-0253-7.

PMID:
25511639
[PubMed - in process]
10.

Strategies for urgent reversal of target-specific oral anticoagulants.

Davis EM, Uhlmeyer EM, Schmidt DP, Schardt GL.

Hosp Pract (1995). 2014 Dec;42(5):108-25. doi: 10.3810/hp.2014.12.1164. Review.

PMID:
25485923
[PubMed - indexed for MEDLINE]
11.

Oral anticoagulation in atrial fibrillation.

Ansari JG, Garcha GS, Lakkis N.

Cardiovasc Hematol Agents Med Chem. 2014;12(1):34-41.

PMID:
25470152
[PubMed - in process]
12.

Novel oral anticoagulants in non-valvular atrial fibrillation.

da Silva RM.

Cardiovasc Hematol Agents Med Chem. 2014;12(1):3-8.

PMID:
25470147
[PubMed - in process]
13.

Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: time for a reappraisal.

Lip GY, Wang KL, Chiang CE.

Int J Cardiol. 2015 Feb 1;180:246-54. doi: 10.1016/j.ijcard.2014.11.182. Epub 2014 Nov 26.

PMID:
25463377
[PubMed - in process]
14.

Management of peri-operative anti-thrombotic therapy.

van Veen JJ, Makris M.

Anaesthesia. 2015 Jan;70 Suppl 1:58-67, e21-3. doi: 10.1111/anae.12900. Review.

PMID:
25440397
[PubMed - indexed for MEDLINE]
15.

Incidence, mortality, and risk factors for oral anticoagulant-associated intracranial hemorrhage in patients with atrial fibrillation.

Grysiewicz R, Gorelick PB.

J Stroke Cerebrovasc Dis. 2014 Nov-Dec;23(10):2479-88. doi: 10.1016/j.jstrokecerebrovasdis.2014.06.031. Epub 2014 Oct 29.

PMID:
25440361
[PubMed - in process]
16.

Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.

Zheng Y, Sorensen SV, Gonschior AK, Noack H, Heinrich-Nols J, Sunderland T, Kansal AR.

Clin Ther. 2014 Dec 1;36(12):2015-2028.e2. doi: 10.1016/j.clinthera.2014.09.015. Epub 2014 Oct 23.

PMID:
25438722
[PubMed - in process]
Free Article
17.

Monitoring and reversal strategies for new oral anticoagulants.

Vanden Daelen S, Peetermans M, Vanassche T, Verhamme P, Vandermeulen E.

Expert Rev Cardiovasc Ther. 2015 Jan;13(1):95-103. doi: 10.1586/14779072.2015.987126. Epub 2014 Nov 28.

PMID:
25431993
[PubMed - in process]
18.

Cost effectiveness of rivaroxaban for stroke prevention in german patients with atrial fibrillation.

Mensch A, Stock S, Stollenwerk B, Müller D.

Pharmacoeconomics. 2015 Mar;33(3):271-83. doi: 10.1007/s40273-014-0236-9.

PMID:
25404426
[PubMed - in process]
19.

Relative efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation by network meta-analysis.

Fu W, Guo H, Guo J, Lin K, Wang H, Zhang Y, Wang Y, Shan Z.

J Cardiovasc Med (Hagerstown). 2014 Dec;15(12):873-9. doi: 10.2459/JCM.0000000000000206.

PMID:
25304034
[PubMed - in process]
Free PMC Article
20.

Stroke and bleeding risk in atrial fibrillation.

Senoo K, Lane D, Lip GY.

Korean Circ J. 2014 Sep;44(5):281-90. doi: 10.4070/kcj.2014.44.5.281. Review.

PMID:
25278980
[PubMed]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk